scholarly journals Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation

Genes ◽  
2021 ◽  
Vol 12 (10) ◽  
pp. 1525
Author(s):  
Seongmin Kim ◽  
Sanghoon Lee ◽  
Hyun-Tae Park ◽  
Jae-Yun Song ◽  
Tak Kim
Keyword(s):  
Fertility Preservation ◽  
Quality Care ◽  
Young Patients ◽  
Young Female ◽  
Patients With Cancer ◽  
Female Cancer Patients ◽  
Ovarian Damage ◽  
Prevention Methods ◽  
Gonadal Damage ◽  
Gene Alterations

Chemotherapy-induced ovarian damage and fertility preservation in young patients with cancer are emerging disciplines. The mechanism of treatment-related gonadal damage provides important information for targeting prevention methods. The genomic aspects of ovarian damage after chemotherapy are not fully understood. Several studies have demonstrated that gene alterations related to follicular apoptosis or accelerated follicle activation are related to ovarian insufficiency and susceptibility to ovarian damage following chemotherapy. This may accelerate follicular apoptosis and follicle reservoir utilization and damage the ovarian stroma via multiple molecular reactions after chemotherapy. This review highlights the importance of genomic considerations in chemotherapy-induced ovarian damage and multidisciplinary oncofertility strategies for providing high-quality care to young female cancer patients.

scholarly journals Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage

2021 ◽  
Vol 22 (14) ◽  
pp. 7484
Author(s):  
Seongmin Kim ◽  
Sung-Woo Kim ◽  
Soo-Jin Han ◽  
Sanghoon Lee ◽  
Hyun-Tae Park ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Radiation Treatment ◽  
Quality Care ◽  
Young Patients ◽  
Young Female ◽  
Clinical Value ◽  
Ovarian Toxicity ◽  
Patients With Cancer ◽  
Ovarian Damage ◽  
Molecular Pathophysiology

Fertility preservation is an emerging discipline, which is of substantial clinical value in the care of young patients with cancer. Chemotherapy and radiation may induce ovarian damage in prepubertal girls and young women. Although many studies have explored the mechanisms implicated in ovarian toxicity during cancer treatment, its molecular pathophysiology is not fully understood. Chemotherapy may accelerate follicular apoptosis and follicle reservoir utilization and damage the ovarian stroma via multiple molecular reactions. Oxidative stress and the radiosensitivity of oocytes are the main causes of gonadal damage after radiation treatment. Fertility preservation options can be differentiated by patient age, desire for conception, treatment regimen, socioeconomic status, and treatment duration. This review will help highlight the importance of multidisciplinary oncofertility strategies for providing high-quality care to young female cancer patients.

scholarly journals Addressing decisional conflict about fertility preservation: helping young female cancer survivors’ family planning decisions

2017 ◽  
Vol 44 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Madleina Müller ◽  
Corinne Urech ◽  
Jacky Boivin ◽  
Verena Ehrbar ◽  
Rebecca Moffat ◽  
...  
Keyword(s):  
Family Planning ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Decisional Conflict ◽  
Young Female ◽  
University Education ◽  
Time Interval ◽  
Related Factors ◽  
Female Cancer Patients

BackgroundHealth professionals are challenged by a growing number of young long-term cancer survivors with their specific needs with regard to family planning. This study aimed at assessing decisional conflict (DC) in young female cancer patients regarding fertility preservation, identifying demographic, fertility and fertility preservation related factors, which may affect DC, and assessing the helpfulness of various decision-supports.MethodsA retrospective, cross-sectional, web-based survey via an online questionnaire available in three languages with specific items concerning cancer, fertility, fertility preservation and the validated Decisional Conflict Scale targeted at current or former female cancer patients aged 18–45 years, with cancer types or treatment potentially affecting reproductive function.ResultsThe 155 participating women showed considerable DC, especially with regard to missing information and support. DC was significantly lower in patients when the risk of infertility was discussed with a health professional, when they had undergone any procedure to preserve fertility, and when they had a university education. A longer time interval since cancer diagnosis was associated with higher DC. The most helpful decision-support tools were specialised websites and leaflets.ConclusionsYoung female cancer patients’ DC with regard to fertility preservation is very high. Information and support seem to be deficient. More information through standardised information tools might be an effective strategy to lower their DC at the time when treatment decisions need to be taken, and to improve their reproductive health after they have overcome cancer in the future.

Fertility preservation for young patients with cancer: who is at risk and what can be offered?

2005 ◽  
Vol 6 (4) ◽  
pp. 209-218 ◽  
Author(s):  
W Hamish B Wallace ◽  
Richard A Anderson ◽  
D Stewart Irvine
Keyword(s):  
At Risk ◽  
Fertility Preservation ◽  
Young Patients ◽  
Patients With Cancer

scholarly journals Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020 ◽  
pp. 331-344 ◽  
Author(s):  
Alexandra S. Rashedi ◽  
Saskia F. de Roo ◽  
Lauren M. Ataman ◽  
Maxwell E. Edmonds ◽  
Adelino Amaral Silva ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Fertility Preservation ◽  
Treatment Plan ◽  
Quality Care ◽  
Global Scale ◽  
Process Improvements ◽  
Patients With Cancer ◽  
Survey Results ◽  
Successes And Challenges ◽  
Legal Barriers

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psychological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that some fertility preservation services are not offered because of cultural and legal barriers. The growth of oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding. Conclusion This survey reveals global and regional successes and challenges and provides insight into what is needed to advance the field and make the discussion of fertility preservation and endocrine health a standard component of the cancer treatment plan. As the field of oncofertility continues to develop around the globe, regular assessment of both international and regional barriers to quality care must continue to guide process improvements.

scholarly journals Fertility Preservation in Female Cancer Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Chung-Hoon Kim ◽  
Gyun-Ho Jeon
Keyword(s):  
Cancer Patients ◽  
Fertility Preservation ◽  
Survival Rates ◽  
Young Patients ◽  
Gynecologic Surgery ◽  
Embryo Cryopreservation ◽  
Future Fertility ◽  
Female Cancer Patients ◽  
Gestational Surrogacy

With improved survival rates among cancer patients, fertility preservation is now being recognized as an issue of great importance. There are currently several methods of fertility preservation available in female cancer patients and the options and techniques via assisted reproduction and cryopreservation are increasing, but some are still experimental and continues to be evaluated. The established means of preserving fertility include embryo cryopreservation, gonadal shielding during radiation therapy, ovarian transposition, conservative gynecologic surgery such as radical trachelectomy, donor embryos/oocytes, gestational surrogacy, and adoption. The experimental methods include oocyte cryopreservation, ovarian cryopreservation and transplantation, in vitro maturation, and ovarian suppression. With advances in methods for the preservation of fertility, providing information about risk of infertility and possible options of fertility preservation to all young patients with cancer, and discussing future fertility with them should be also considered as one of the important parts of consultation at the time of cancer diagnosis.

scholarly journals Fertility Preservation for Pre-Pubertal Girls and Young Female Cancer Patients

10.5772/24932 ◽  
2012 ◽  
Author(s):  
R. Gerritse ◽  
L. Bastings ◽  
C.C.M. Beerendonk ◽  
J.R. Westphal ◽  
D.D.M. Braat ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Fertility Preservation ◽  
Young Female ◽  
Female Cancer Patients

scholarly journals Follicle Rescue From Prepubertal Ovaries After Recent Treatment With Cyclophosphamide—An Experimental Culture System Using Mice to Achieve Mature Oocytes for Fertility Preservation

2021 ◽  
Vol 11 ◽  
Author(s):  
Xia Hao ◽  
Amandine Anastácio ◽  
Laia Viñals-Ribé ◽  
Ana Santamaria Lacuesta ◽  
Christina Diakaki ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Ovarian Tissue ◽  
Young Patients ◽  
Ovarian Tissue Cryopreservation ◽  
Ovarian Tissue Transplantation ◽  
Oocyte Competence ◽  
Patients With Cancer ◽  
Tissue Cryopreservation ◽  
Selection Of

Ovarian tissue cryopreservation is the only feasible method for fertility preservation in prepubertal girls that will undergo gonadotoxic chemotherapy. To date, the only clinical use of cryopreserved tissue is by a later tissue retransplantation to the patient. Clinical challenges in fertility preservation of very young patients with cancer include time constraints that do not allow to retrieve the tissue for cryopreservation before starting chemotherapy and the preclusion of future ovarian tissue transplantation due to the risk of reintroduction of malignant cells in patients with systemic diseases. To overcome these two challenges, we investigated using an experimental model the feasibility of retrieving secondary follicles from ovaries of prepubertal mice after cyclophosphamide (CPA) treatment in increasing doses of 50, 75, and 100 mg/kg. The follicles were thereafter cultured and matured in vitro. The main outcomes included the efficiency of the method in terms of obtained matured oocytes and the safety of these potentially fertility preservative procedures in terms of analyses of oocyte competence regarding normality of the spindle and chromosome configurations. Our findings demonstrated that it was feasible to isolate and culture secondary follicles and to obtain mature oocytes from prepubertal mice ovaries recently treated with CPA. The efficiency of this method was highly demonstrated in the 100 mg/kg CPA group, with near 90% follicle survival rate after 12 days’ culture, similarly to control. Around 80% of the follicles met the criteria to put into maturation, and more than 40% of them achieved metaphase II, with normal spindle and chromosome configurations observed. Suboptimal results were obtained in the 50 and 75 mg/kg CPA groups. These paradoxical findings towards CPA dose might probably reflect a more difficult selection of damaged growing follicles from ovaries recently treated with lower doses of CPA and a hampered ability to identify and discard those with reduced viability for the culture.

Sign in / Sign up

Export Citation Format

Share Document